The World Stroke Organization reports that "Stroke has already reached epidemic proportions. Globally 1 in 4 adults over the age of 25 will have a stroke in their lifetime. 12.2 million people worldwide will have their first stroke this year and 6.5 million will die as a result. Over 110 million people in the world have experienced stroke." Ischemic strokes are the most common type of stroke, with about 87% of all strokes being ischemic strokes.
This new volume helps to address this epidemic by presenting detailed studies on ischemic injury, with emphasis on the molecular-level mechanisms and the role of signaling pathways in the body, their structure, and their mechanism of action. The book focuses on molecular pharmacology plans and explains the new areas of research on the discovery of new therapeutic molecules that can be used for combating this life-threatening disease.
The significant etiologies of ischemic and hemorrhagic stroke are reviewed in detail. The authors discuss stroke occurrence at different stages of life, such as sex-based differences in the treatment of ischemic injury. The COVID-19 pandemic has created an elevated incidence and risk of ischemic stroke, which is addressed in the volume. The authors cover aspects of the clinical treatment and diagnosis of patients with cardiovascular events, including in-depth information on the prevention, evaluation, therapy selection, result projection, and long-term course of the disease in affected patients. The authors describe the effect of stroke in daily life as well as complications for prevention of stroke. They also detail the involvement of platelets, neurotransmitters, renin-angiotensin-aldosterone system, and vitamin-D in ischemic injury. This book outlines the various aspects of recognizable proof of preclinical and clinical improvement
This book also looks at the pharmacological aspects that incorporate physiology of a disease, receptor-connected intracellular weak structure, different transduction pathways, and multiple I/R injuries.
Medical researchers, medical students, and medical and neurology residents who handle patients with acute stroke syndromes will find this volume to be a valuable resource. The book will be important to experts on the cutting-edge of molecular pharmacology, detailing the most recent improvements in cell and receptors pharmacology with a noteworthy emphasis on the system of activity of novel medications being worked on for ischemic injury.